Compare General Motors Company (GM) vs Heron Therapeutics Inc (HRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Motors Company vs Heron Therapeutics Inc — how do they compare? General Motors Company trades at $82.5 (market cap $71.06B), while Heron Therapeutics Inc trades at $0.37 (market cap $74.04M). The key difference: General Motors Company is far larger — about 959.8× Heron Therapeutics Inc's market cap, and General Motors Company pays a 0.89% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold General Motors Company for 83 Days and Heron Therapeutics Inc for 35 Days on average.
| GM | HRTX | |
|---|---|---|
Market Cap | $71.06B | $74.04M |
Volume | 6,269,264 | 3,668,095 |
Sector | Consumer Cyclical | Health |
52-Week High | $90.30 | $1.49 |
52-Week Low | $55.35 | $0.27 |
Typical Hold Time | 83 Days | 35 Days |
Enterprise Value | $174.04B | $180.78M |
Dividend Yield | 0.89% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Motors (GM) trades at $82.25, up 0.29% with a bearish technical signal despite recent earnings beats. The stock shows mixed fundamentals with declining revenue and net income margins (1.05% in 2025) but attractive valuation ratios including P/S of 0.41. Recent news highlights competitive pressures as Toyota narrows the U.S. sales gap and Q3 2026 sales fell 5.5% amid EV challenges.
GM faces headwinds from market share erosion and profitability pressure, though analyst consensus remains bullish with a $102.08 price target. Investment appeal hinges on execution amid industry transition, with risks including high debt levels and competitive threats from Asian automakers.
HRTX trades at $0.39, up 17.58% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings performance discussions.
The outlook is mixed: strong analyst support and technical momentum suggest potential upside, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on revenue growth translating to profitability, while key risks include execution challenges and competitive pressures in the biotechnology sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About General Motors Company
General Motors Co. emerged from the bankruptcy of General Motors Corp. (old GM) in July 2009. GM has eight brands and operates under four segments: GM North America, GM International, Cruise, and GM Financial. The United States now has four brands instead of eight under old GM. The company lost its U.S. market share leader crown in 2021 with share down 280 basis points to 14.6%, but we expect GM to reclaim the top spot in 2022 as 2021 suffered from the chip shortage. GM Financial became the company's captive finance arm in October 2010 via the purchase of AmeriCredit.
Read more on GM →About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →
